太阳集团1088vip十周年院慶系列活動­之藥學前沿大講堂第124講

Structure-based Antiviral Drug Discovery: Case Studies of Anti-Influenza, HIV and Hepatitis Agents

發布人:高級管理員 發布日期:2012-08-15
主題
Structure-based Antiviral Drug Discovery: Case Studies of Anti-Influenza, HIV and Hepatitis Agents
活動時間
-
活動地址
中山大學東校區太阳集团1088vip 125講學廳
主講人
Xiaowu Chen(陳小五)Ph.D.
主持人
徐 峻 教授

太阳集团1088vip十周年院慶系列活動­————

藥學前沿大講堂第124

 

  目:Structure-based Antiviral Drug Discovery: Case Studies of Anti-Influenza, HIV and Hepatitis Agents

報告人:Xiaowu Chen(陳小五)Ph.D.

               Sr. Scientist, molecular modeling and structure-based drug discovery, Gilead Sciences, Foster City, California

主持人:徐 教授    太阳集团1088vip

  間:2012821日(周二) 下午2:30

  點:中山大學東校區太阳集团1088vip  125講學廳

報告内容:

Viral diseases pose significant threats to humanity.  Influenza, HIV, and hepatitis infections account for majority of deadly viral diseases.  So far Tamiflu is the only oral anti-influenza drug with broad spectrum activity.  During the discovery of Tamiflu at Gilead, an unusual hydrophobic-polar π interaction between charged amino acids of influenza neuraminidase and hydrophobic moiety of Tamiflu has been identified, such interaction is crucial for Tamiflu’s potency. This observation is against conventional thinking in terms of molecular interactions and may provide an additional dimension in future molecular interaction and drug design.  Hepatitis C NS3 protease is another interesting viral target that has attracted significant effort from both academia and pharmaceutical industry.  A scaffold-dependent structure-activity relationship (SAR)  have been predicted by molecular modeling and validated by experimental results. Details of these discoveries will be discussed.

報告人介紹:

    陳小五博士于1984年在廈門大學化學系取得物理化學專業的學士學位,并于1993年在美國賓夕法尼亞州立大學獲得生物物理學/物理化學專業的博士學位。于1993-1997年期間在美國加利福尼亞大學進行博士後研究工作。其後,于1997年至今在Gilead Sciences 公司進行分子模拟和基于結構的藥物設計研究工作。 陳博士與合作者已獲得美國授權專利11項。此外,陳博士還多次被邀請在重大學術會議上做口頭報告,并在國際重要期刊上發表論文37餘篇。